Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.

HRD/ BRCA tumors, like MSI tumors, more frequently had PD-L1 + immune cells in ≥1% of tumor area, but this difference did not reach statistical significance (53% vs 30%, p = .18).

also in 111,027 other papers